0000000000410046

AUTHOR

Arvydas Laurinavicius

showing 2 related works from this author

Genotype–phenotype correlation in a new Fabry-disease-causing mutation

2019

Background: Fabry disease (FD) is a rare X-linked inherited lysosomal storage disorder caused by α-galactosidase A deficiency leading to intracellular glycosphingolipid accumulation. FD manifestation is multisystem, and can differ depending on disease-related genetic variants. Currently, more than 700 different FD-causing mutations have been identified in the human GLA gene. We identified a novel mutation in a Lithuanian family with classical manifestations of Fabry disease, revealing severe effects to the cardiovascular systems of heterozygous women. Case presentation: A 49-year-old woman underwent echocardiography due to progressive dyspnea that lasted seven years, reduced physical a…

Probandmedicine.medical_specialtyAbdominal painMedicine (General)α-galactosidase ACase ReportLeft ventricular hypertrophyGastroenterologyclassical manifestationR5-920Internal medicinemedicineGLA geneFabry diseasemedicine.diagnostic_testbusiness.industryCardiac arrhythmiaGeneral MedicineFabry disease ; α-galactosidase A ; GLA gene ; novel mutation ; classical manifestationmedicine.diseaseFabry diseaseHyperintensityMutation (genetic algorithm)<i>GLA</i> geneRenal biopsymedicine.symptomnovel mutationbusiness
researchProduct

Renal Survival and Validation of Novel International Immunoglobulin a Nephropathy Prediction Tool in Latvian Population: Preliminary Data

2021

Abstract The aim of the study was to determine kidney survival and validate the novel international immunoglobulin A nephropathy (IgAN) prediction tool (PT) in the Latvian population. Adults with morphologically confirmed IgAN were included. Kidney survival was analysed with the Kaplan–Meier method. PT-assigned risk was compared with calculated risk by the Cox regression model. The Kaplan–Meier analysis included 95 patients. The five-year kidney survival Q3 was 24 months. Women had longer median kidney-survival time (&gt; 60 months) than men (58 months). Median kidney survival in participants with MEST T0 was longer than 60 months; T1 and T2 were 40 and 18 months, respectively. Median kidne…

Oncologymedicine.medical_specialtyeducation.field_of_studybusiness.industryPopulationLatvianlanguage.human_languageInternal medicinemedicinelanguageImmunoglobulin A NephropathybusinesseducationRenal survivalProceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.
researchProduct